Suscribirse

Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity - 04/11/21

Doi : 10.1016/j.jaci.2021.08.016 
Ottavia M. Delmonte, MD, PhD a, , Jenna R.E. Bergerson, MD a, , Peter D. Burbelo, PhD b, , Jessica R. Durkee-Shock, MD c, Kerry Dobbs, BS a, Marita Bosticardo, PhD a, Michael D. Keller, MD c, David H. McDermott, MD d, V. Koneti Rao, MD a, Dimana Dimitrova, MD e, Eugenia Quiros-Roldan, MD f, g, Luisa Imberti, MD g, Elise M.N. Ferrè, PA-C a, Monica Schmitt, CRNP a, Christine Lafeer, RN a, Justina Pfister, RN a, Dawn Shaw, RN a, Deborah Draper, RN a, Meng Truong, RN a, Jean Ulrick, RN a, Tom DiMaggio, RN a, Amanda Urban, DNP a, Steven M. Holland, MD a, Michail S. Lionakis, MD, ScD a, Jeffrey I. Cohen, MD h, Emily E. Ricotta, PhD a, , Luigi D. Notarangelo, MD a, , , Alexandra F. Freeman, MD a, ,
a Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md 
b National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Md 
c Center for Cancer and Immunology Research and Division of Allergy and Immunology, Children’s National Hospital, Washington, DC 
d Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md 
e Experimental Transplantation and Immunotherapy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md 
f Department of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili di Brescia, Brescia, Italy 
g CREA Laboratory, Diagnostic Laboratory, ASST Spedali Civili di Brescia, Brescia, Italy 
h Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md 

Corresponding author: Alexandra Freeman, MD, Building 10, Room 12C103, National Institutes of Health, 10 Center Dr, Bethesda, MD 20892.Building 10, Room 12C103, National Institutes of Health10 Center DrBethesdaMD20892∗∗Luigi D. Notarangelo, MD, Building 10, Room 5-3950, National Institutes of Health, 10 Center Dr, Bethesda, MD 20892.Building 10, Room 5-3950, National Institutes of Health10 Center DrBethesdaMD20892

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Background

SARS-CoV-2 vaccination is recommended in patients with inborn errors of immunity (IEIs); however, little is known about immunogenicity and safety in these patients.

Objective

We sought to evaluate the impact of genetic diagnosis, age, and treatment on antibody response to COVID-19 vaccine and related adverse events in a cohort of patients with IEIs.

Methods

Plasma was collected from 22 health care worker controls, 81 patients with IEIs, and 2 patients with thymoma; the plasma was collected before immunization, 1 to 6 days before the second dose of mRNA vaccine, and at a median of 30 days after completion of the immunization schedule with either mRNA vaccine or a single dose of Johnson & Johnson’s Janssen vaccine. Anti-spike (anti-S) and anti-nucleocapsid antibody titers were measured by using a luciferase immunoprecipitation systems method. Information on T- and B-cell counts and use of immunosuppressive drugs was extracted from medical records, and information on vaccine-associated adverse events was collected after each dose.

Results

Anti-S antibodies were detected in 27 of 46 patients (58.7%) after 1 dose of mRNA vaccine and in 63 of 74 fully immunized patients (85.1%). A lower rate of seroconversion (7 of 11 [63.6%]) was observed in patients with autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy. Previous use of rituximab and baseline counts of less than 1000 CD3+ T cells/mL and less than 100 CD19+ B cells/mL were associated with lower anti-S IgG levels. No significant adverse events were reported.

Conclusion

Vaccinating patients with IEIs is safe, but immunogenicity is affected by certain therapies and gene defects. These data may guide the counseling of patients with IEIs regarding prevention of SARS-CoV-2 infection and the need for subsequent boosts.

El texto completo de este artículo está disponible en PDF.

Key words : SARS-CoV-2, antibody response, COVID-19, inborn errors of immunity, immunomodulators, immune suppressants, JAK inhibitors, adverse events

Abbreviations used : anti-N, Anti-S, APECED, GM, HCW, IEI, LU


Esquema


 Supported by the Intramural Research programs of the National Institute of Dental and Craniofacial Research and the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant 1 ZIA AI001270-01[to L.D.N.]) and Regione Lombardia (the project Risposta immune in pazienti con COVID-19 e co-morbidità).
 Disclosure of potential conflict of interest: L. D. Notarangelo declares receipt of royalty payments from UpToDate. The rest of the authors declare that they have no relevant conflicts of interest.


© 2021  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 148 - N° 5

P. 1192-1197 - novembre 2021 Regresar al número
Artículo precedente Artículo precedente
  • Immunologic resilience and COVID-19 survival advantage
  • Grace C. Lee, Marcos I. Restrepo, Nathan Harper, Muthu Saravanan Manoharan, Alisha M. Smith, Justin A. Meunier, Sandra Sanchez-Reilly, Aamir Ehsan, Anne P. Branum, Caitlyn Winter, Lauryn Winter, Fabio Jimenez, Lavanya Pandranki, Andrew Carrillo, Graciela L. Perez, Antonio Anzueto, Hanh Trinh, Monica Lee, Joan M. Hecht, Celida Martinez-Vargas, Raj T. Sehgal, Jose Cadena, Elizabeth A. Walter, Kimberly Oakman, Raymond Benavides, Jacqueline A. Pugh, South Texas Veterans Health Care System COVID-19 Team, Scott Letendre, Maristella Steri, Valeria Orrù, Edoardo Fiorillo, Francesco Cucca, Alvaro G. Moreira, Nu Zhang, Elizabeth Leadbetter, Brian K. Agan, Douglas D. Richman, Weijing He, Robert A. Clark, Jason F. Okulicz, Sunil K. Ahuja, Mohamed I. Abdalla, Sandra G. Adams, Joseph Agnew, Saleem Ali, Jennifer Barker, Angela Birdwell, Stephen Bradford, Heather Briggs, Judith Marin Corral, Jennifer J. Dacus, Patrick J. Danaher, Scott A. DePaul, Jill Dickerson, Jollynn Doanne, Samantha Elbel, Corina Escamilla, Robert Farrar, David Feldman, Julianne Flynn, Delvina Ford, Joanna D. Foy, Megan Freeman, Samantha Galley, Maritza Garza, Sherraine Gilman, Jennifer Gomez, Varun K. Goyal, Sally Grassmuck, Joshua Hanson, Brande Harris, Gabrielyd Hastings, Audrey Haywood, Cecilia Hinojosa, Tony T. Ho, Teri Hopkins, Pamela Jewell, Thomas B. Johnson, Vasiliki Kotogiannes, Austin C. Lawler, Chadwick S. Lester, Stephanie M. Levine, Haidee V. Lewis, Angel Louder, Charmaine Mainor, Rachel Maldonado, Yvette Martinez, Neil McElligott, Laura Medlin, Myra Mireles, Kathleen Morneau, Samuel B. Munro, Anoop Nambiar, Daniel Nassery, Robert Nathanson, Jane O’Rorke, Cheryl Padgett, Sergi Pascual-Guardia, Marisa Patterson, Rogelio Perez, Robert E. Phillips, Patrick B. Polk, Michael A. Pomager, Kristy J. Preston, Kevin C. Proud, Michelle Rangel, Temple A. Ratcliffe, Renee L. Reichelderfer, Evan M. Renz, Jeanette Ross, Teresa Rudd, Maria E. Sanchez, Tammy Sanders, Kevin C. Schindler, David Schmit, Claudio Solorzano, Nilam Soni, Win S. Tam, Edward J. Tovar, Anna R. Tyler, Anjuli Vasquez, Maria C. Veloso, Steven G. Venticinque, Jorge A. Villalpando, Melissa Villanueva, Lauren Villegas, Andrew Wallace, Emily Wang, Andreia Williamson, Sadie A. Trammell Velasquez, Andrea Yunes, Katharine H. Zentner
| Artículo siguiente Artículo siguiente
  • Endotype of allergic asthma with airway obstruction in urban children
  • Matthew C. Altman, Agustin Calatroni, Sima Ramratnam, Daniel J. Jackson, Scott Presnell, Mario G. Rosasco, Peter J. Gergen, Leonard B. Bacharier, George T. O’Connor, Megan T. Sandel, Meyer Kattan, Robert A. Wood, Cynthia M. Visness, James E. Gern, Inner City Asthma Consortium

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.